Shanghai Haohai Biological Technology Co., Ltd. (HKG: 6826)

Market Cap	14.71B
Revenue (ttm)	3.04B
Net Income (ttm)	476.51M
Shares Out	230.55M
EPS (ttm)	1.45
PE Ratio	20.02
Forward PE	13.08
Dividend	0.86 (2.93%)
Ex-Dividend Date	Sep 20, 2024

Volume	279,300
Open	29.30
Previous Close	29.40
Day's Range	28.70 - 29.80
52-Week Range	21.71 - 42.95
Beta	0.74
Analysts	n/a
Price Target	n/a
Earnings Date	Oct 25, 2024

About Shanghai Haohai Biological Technology

Shanghai Haohai Biological Technology Co., Ltd. engages in the research, development, manufacture, and sale of biomedical materials in China, Europe, the United States, and internationally. The company offers ophthalmology products consisting intraocular lens, medical sodium hyaluronate gel, and lubricant eye drop. It also offers sodium hyaluronate injection, medical chitosan, sodium hyaluronate gel, sodium hyaluronate gel, anti adhesion, and burn wound related products. In addition, the company provides injectors, scalpels, and suture needles....

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2007
• Employees: 2,158
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 6826

Financial Performance

In 2023, Shanghai Haohai Biological Technology's revenue was 2.65 billion, an increase of 24.59% compared to the previous year's 2.13 billion. Earnings were 416.12 million, an increase of 130.58%.

Financial numbers in CNY